The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor pqip exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models

Sara A. Flanigan, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, Aik-Choon Tan, Andrew Thorburn, Stephen Leong

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: There is growing evidence implicating the importance of the insulin-like growth factor (IGF) pathway in colorectal cancer based upon the results of population studies and preclinical experiments. However, the combination of an IGF-I receptor (IGF-IR) inhibitor with standard colorectal cancer chemotherapies has not yet been evaluated. In this study, we investigated the interaction between PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard chemotherapies in colorectal cancer cell line models. Experimental Design: The antiproliferative effects of PQIP, as a single agent and in combination with 5-fluorouracil, oxaliplatin, or SN38, were analyzed against four colorectal cancer cell lines. Downstream effector proteins, apoptosis, and cell cycle were also assessed in the combination of PQIP and SN-38. Lastly, the efficacy of OSI-906 (a derivative of PQIP) combined with irinotecan was further tested using a human colorectal cancer xenograft model. Results: Treatment with the combination of PQIP and each of three chemotherapies resulted in an enhanced decrease in proliferation of all four colorectal cancer cell lines compared with single-agent treatment. This inhibition was not associated with a significant induction of apoptosis, but was accompanied by cell cycle arrest and changes in phosphorylation of Akt. Interestingly, antitumor activity between PQIP and SN-38 in vitro was also reflected in the human colorectal cancer xenograft model. Conclusions: Combination treatment with PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard colorectal cancer chemotherapy resulted in enhanced antiproliferative effects against colorectal cancer cell line models, providing a scientific rationale for the testing of OSI-906 and standard colorectal cancer treatment regimens.

Original languageEnglish
Pages (from-to)5436-5446
Number of pages11
JournalClinical Cancer Research
Volume16
Issue number22
DOIs
Publication statusPublished - 2010 Nov 15
Externally publishedYes

Fingerprint

IGF Type 1 Receptor
Combination Drug Therapy
Colorectal Neoplasms
irinotecan
Somatomedins
Drug Therapy
Cell Line
oxaliplatin
Heterografts
insulin receptor tyrosine kinase
Apoptosis
Cell Cycle Proteins
Therapeutics
Cell Cycle Checkpoints
Fluorouracil
Research Design
Phosphorylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor pqip exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. / Flanigan, Sara A.; Pitts, Todd M.; Eckhardt, S. Gail; Tentler, John J.; Tan, Aik-Choon; Thorburn, Andrew; Leong, Stephen.

In: Clinical Cancer Research, Vol. 16, No. 22, 15.11.2010, p. 5436-5446.

Research output: Contribution to journalArticle

Flanigan, Sara A. ; Pitts, Todd M. ; Eckhardt, S. Gail ; Tentler, John J. ; Tan, Aik-Choon ; Thorburn, Andrew ; Leong, Stephen. / The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor pqip exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 22. pp. 5436-5446.
@article{8670bac3909842d987c62ea8ca1f1549,
title = "The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor pqip exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models",
abstract = "Purpose: There is growing evidence implicating the importance of the insulin-like growth factor (IGF) pathway in colorectal cancer based upon the results of population studies and preclinical experiments. However, the combination of an IGF-I receptor (IGF-IR) inhibitor with standard colorectal cancer chemotherapies has not yet been evaluated. In this study, we investigated the interaction between PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard chemotherapies in colorectal cancer cell line models. Experimental Design: The antiproliferative effects of PQIP, as a single agent and in combination with 5-fluorouracil, oxaliplatin, or SN38, were analyzed against four colorectal cancer cell lines. Downstream effector proteins, apoptosis, and cell cycle were also assessed in the combination of PQIP and SN-38. Lastly, the efficacy of OSI-906 (a derivative of PQIP) combined with irinotecan was further tested using a human colorectal cancer xenograft model. Results: Treatment with the combination of PQIP and each of three chemotherapies resulted in an enhanced decrease in proliferation of all four colorectal cancer cell lines compared with single-agent treatment. This inhibition was not associated with a significant induction of apoptosis, but was accompanied by cell cycle arrest and changes in phosphorylation of Akt. Interestingly, antitumor activity between PQIP and SN-38 in vitro was also reflected in the human colorectal cancer xenograft model. Conclusions: Combination treatment with PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard colorectal cancer chemotherapy resulted in enhanced antiproliferative effects against colorectal cancer cell line models, providing a scientific rationale for the testing of OSI-906 and standard colorectal cancer treatment regimens.",
author = "Flanigan, {Sara A.} and Pitts, {Todd M.} and Eckhardt, {S. Gail} and Tentler, {John J.} and Aik-Choon Tan and Andrew Thorburn and Stephen Leong",
year = "2010",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-10-2054",
language = "English",
volume = "16",
pages = "5436--5446",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor pqip exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models

AU - Flanigan, Sara A.

AU - Pitts, Todd M.

AU - Eckhardt, S. Gail

AU - Tentler, John J.

AU - Tan, Aik-Choon

AU - Thorburn, Andrew

AU - Leong, Stephen

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Purpose: There is growing evidence implicating the importance of the insulin-like growth factor (IGF) pathway in colorectal cancer based upon the results of population studies and preclinical experiments. However, the combination of an IGF-I receptor (IGF-IR) inhibitor with standard colorectal cancer chemotherapies has not yet been evaluated. In this study, we investigated the interaction between PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard chemotherapies in colorectal cancer cell line models. Experimental Design: The antiproliferative effects of PQIP, as a single agent and in combination with 5-fluorouracil, oxaliplatin, or SN38, were analyzed against four colorectal cancer cell lines. Downstream effector proteins, apoptosis, and cell cycle were also assessed in the combination of PQIP and SN-38. Lastly, the efficacy of OSI-906 (a derivative of PQIP) combined with irinotecan was further tested using a human colorectal cancer xenograft model. Results: Treatment with the combination of PQIP and each of three chemotherapies resulted in an enhanced decrease in proliferation of all four colorectal cancer cell lines compared with single-agent treatment. This inhibition was not associated with a significant induction of apoptosis, but was accompanied by cell cycle arrest and changes in phosphorylation of Akt. Interestingly, antitumor activity between PQIP and SN-38 in vitro was also reflected in the human colorectal cancer xenograft model. Conclusions: Combination treatment with PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard colorectal cancer chemotherapy resulted in enhanced antiproliferative effects against colorectal cancer cell line models, providing a scientific rationale for the testing of OSI-906 and standard colorectal cancer treatment regimens.

AB - Purpose: There is growing evidence implicating the importance of the insulin-like growth factor (IGF) pathway in colorectal cancer based upon the results of population studies and preclinical experiments. However, the combination of an IGF-I receptor (IGF-IR) inhibitor with standard colorectal cancer chemotherapies has not yet been evaluated. In this study, we investigated the interaction between PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard chemotherapies in colorectal cancer cell line models. Experimental Design: The antiproliferative effects of PQIP, as a single agent and in combination with 5-fluorouracil, oxaliplatin, or SN38, were analyzed against four colorectal cancer cell lines. Downstream effector proteins, apoptosis, and cell cycle were also assessed in the combination of PQIP and SN-38. Lastly, the efficacy of OSI-906 (a derivative of PQIP) combined with irinotecan was further tested using a human colorectal cancer xenograft model. Results: Treatment with the combination of PQIP and each of three chemotherapies resulted in an enhanced decrease in proliferation of all four colorectal cancer cell lines compared with single-agent treatment. This inhibition was not associated with a significant induction of apoptosis, but was accompanied by cell cycle arrest and changes in phosphorylation of Akt. Interestingly, antitumor activity between PQIP and SN-38 in vitro was also reflected in the human colorectal cancer xenograft model. Conclusions: Combination treatment with PQIP, the dual IGF-IR/insulin receptor tyrosine kinase inhibitor, and standard colorectal cancer chemotherapy resulted in enhanced antiproliferative effects against colorectal cancer cell line models, providing a scientific rationale for the testing of OSI-906 and standard colorectal cancer treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=78349254271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349254271&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2054

DO - 10.1158/1078-0432.CCR-10-2054

M3 - Article

VL - 16

SP - 5436

EP - 5446

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -